A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by
an acute and rapid deterioration of liver function in a patient with previously
well-compensated liver disease owing to the effects of a precipitating event. In this
condition two insults act simultaneously, one being the preexisting liver injury (chronic
liver disease) and the other acute injury which is responsible for the acute decompensation.
HEV being a major factor responsible for this clinical entity and has a very high mortality
rate. Ribavirin being a safe drug and has been shown to inhibit the replication of HEV, can
be an important drug in the treatment of these patients. Therefore the present study is
designed to study the impact of Ribavirin in reducing the mortality due to HEV related ACLF.
Phase:
Phase 2
Details
Lead Sponsor:
All India Institute of Medical Sciences, New Delhi